For instance, AAV (adeno-associated virus)-mediated gene therapy has shown promise in conditions such as ornithine transcarbamylase (OTC) deficiency, Fabry disease, and spinal muscular atrophy (98). This evidence concerns the gene OTC and ornithine carbamoyltransferase deficiency.